reports
Abivax: 1 director
A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
- Jerôme Bodin
CLN CLARIANT AG
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
MF WENDEL SE
INF INFOTEL SA
DEC JCDECAUX SA
FAGR FAGRON SA
NTG NETGEM SA
MRN MERSEN SA
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BB SOCIETE BIC SA
NEX NEXANS SA
ERA ERAMET SA
ELIS ELIS SA
AIXA AIXTRON SE
VIS VISCOFAN S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
MELE MELEXIS NV
CSM CORBION NV
SPIE SPIE SA
MEL MELIA HOTELS INTERNATIONAL S.A.
TKO TIKEHAU CAPITAL SCA
DUFN DUFRY AG
ALD ALD SA
MEDCL MEDINCELL SA
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
TE TECHNIP ENERGIES NV
ALHRS HYDROGEN REFUELING SOLUTIONS
HGEA HGEARS AG
AZE AZELIS GROUP NV
IVG IVECO GROUP
FLOW FLOW TRADERS LTD
AF AIR FRANCE - KLM
ORP ORPEA
PLNW PLANISWARE
EXENS EXOSENS
LOCAL SOLOCAL GROUP
HBX HBX GROUP INTERNATIONAL PLC
- Jerôme Bodin
CLN CLARIANT AG
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
MF WENDEL SE
INF INFOTEL SA
DEC JCDECAUX SA
FAGR FAGRON SA
NTG NETGEM SA
MRN MERSEN SA
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BB SOCIETE BIC SA
NEX NEXANS SA
ERA ERAMET SA
ELIS ELIS SA
AIXA AIXTRON SE
VIS VISCOFAN S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
MELE MELEXIS NV
CSM CORBION NV
SPIE SPIE SA
MEL MELIA HOTELS INTERNATIONAL S.A.
TKO TIKEHAU CAPITAL SCA
DUFN DUFRY AG
ALD ALD SA
MEDCL MEDINCELL SA
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
ZEL PHARMA MAR SA
TCH TECHNICOLOR SA
TE TECHNIP ENERGIES NV
ALHRS HYDROGEN REFUELING SOLUTIONS
HGEA HGEARS AG
AZE AZELIS GROUP NV
IVG IVECO GROUP
FLOW FLOW TRADERS LTD
AF AIR FRANCE - KLM
ORP ORPEA
PLNW PLANISWARE
EXENS EXOSENS
LOCAL SOLOCAL GROUP
HBX HBX GROUP INTERNATIONAL PLC
- Nicolas Thorez
- Nicolas Thorez
- Juan Ros-Padilla
MT ARCELORMITTAL SA
BEKB BEKAERT SA
NK IMERYS SA
AUTN AUTONEUM HOLDING AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
SZG SALZGITTER AG
ABVX ABIVAX SA
OERL OC OERLIKON CORPORATION AG
CDA COMPAGNIE DES ALPES SA
ALTA ALTAREA SCA
VOE VOESTALPINE AG
ACX ACERINOX SA
EBRO EBRO FOODS SA
SOLB SOLVAY SA
NEX NEXANS SA
ERA ERAMET SA
COR CORTICEIRA AMORIM SGPS SA
NDA AURUBIS AG
KRN KRONES AG
PAL PALFINGER AG
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
MELE MELEXIS NV
ZAG ZUMTOBEL GROUP AG
TWEKA TKH GROUP N.V. CERT
WLN WORLDLINE SA
IBG IBERPAPEL GESTION S.A.
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
SMCP SMCP SA
BFSA BEFESA SA
AMAG AMAG AUSTRIA METALL AG
THEP THERMADOR HOLDING SA
VRLA VERALLIA SAS
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
EAPI EUROAPI
BRE BREMBO S.P.A.
EXENS EXOSENS
CO CASINO GUICHARD-PERRACHON
HAVAS HAVAS N.V
CAN CANAL+
HBX HBX GROUP INTERNATIONAL PLC
AAL ANGLO AMERICAN PLC
- Juan Ros-Padilla
MT ARCELORMITTAL SA
BEKB BEKAERT SA
NK IMERYS SA
AUTN AUTONEUM HOLDING AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
SZG SALZGITTER AG
ABVX ABIVAX SA
OERL OC OERLIKON CORPORATION AG
CDA COMPAGNIE DES ALPES SA
ALTA ALTAREA SCA
VOE VOESTALPINE AG
ACX ACERINOX SA
EBRO EBRO FOODS SA
SOLB SOLVAY SA
NEX NEXANS SA
ERA ERAMET SA
COR CORTICEIRA AMORIM SGPS SA
NDA AURUBIS AG
KRN KRONES AG
PAL PALFINGER AG
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
MELE MELEXIS NV
ZAG ZUMTOBEL GROUP AG
TWEKA TKH GROUP N.V. CERT
WLN WORLDLINE SA
IBG IBERPAPEL GESTION S.A.
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
SMCP SMCP SA
BFSA BEFESA SA
AMAG AMAG AUSTRIA METALL AG
THEP THERMADOR HOLDING SA
VRLA VERALLIA SAS
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
EAPI EUROAPI
BRE BREMBO S.P.A.
EXENS EXOSENS
CO CASINO GUICHARD-PERRACHON
HAVAS HAVAS N.V
CAN CANAL+
HBX HBX GROUP INTERNATIONAL PLC
AAL ANGLO AMERICAN PLC
- Martial Descoutures
Abivax : A well-deserved success, Outperform confirmed
We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.
- Martial Descoutures
Abivax : Un succès bien mérité, Surperformance confirmée
Nous relevons significativement notre OC de 24 € à 88 € suite aux résultats positifs de la phase 3 (ABTECT) en induction d’obefazimod dans la rectocolite hémorragique. Obefazimod a atteint des taux de rémission clinique significatifs supérieurs à ceux observés en phase 2b, et comparables aux meilleurs agents en développement. Suite à ces résultats, nous croyons qu’Abivax est une cible crédible d’acquisition pour une Pharma voulant se renforcer en Immunologie. Recommandation Surperformance réitér...
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Closing of $747.5 Million Public Offering Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each r...
- Anthony Dick
- Emira Sagaama
- Margaux van Oerle
- Michael Foundoukidis
- Usama Tariq
SOP SOPRA STERIA GROUP SA
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
BIO BB BIOTECH AG
POM PLASTIC OMNIUM SE
MERY MERCIALYS SA
ASY ASSYSTEM SA
BEN BENETEAU SA
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
FII LISI SA
LSS LECTRA SA
LNA LNA SANTE SA
GBT GUERBET SA
ATE ALTEN SA
ACX ACERINOX SA
FR VALEO SE
BAMNB KONINKLIJKE BAM GROEP NV
FAE FAES FARMA S.A.
COFB COFINIMMO SA
SUN SULZER AG
TUB TUBACEX S.A.
HEIJM HEIJMANS N.V. CERT
MBWS
CTAC MARIE BRIZARD WINE & SPIRITS SA
PAL CTAC N.V.
CON PALFINGER AG
LIGHT CONZZETA AG
NVG SIGNIFY NV
WBD NAVIGATOR COMPANY SA
RENE WEBUILD S.P.A.
ROVI REDES ENERGETICAS NACIONAIS SA
COL LABORATORIOS FARMACEUTICOS ROVI S.A.
ALM INMOBILIARIA COLONIAL SOCIMI SA
TEC ALMIRALL SA
HOME TECHNIPFMC PLC
VOS NEINOR HOMES SA
2CRSI VOSSLOH AG
VK 2CRSI SA
WDP VALLOUREC SA
ALHG WAREHOUSES DE PAUW SCA
LOUIS HACHETTE GROUP
- Anthony Dick
- Emira Sagaama
- Margaux van Oerle
- Michael Foundoukidis
- Usama Tariq
SOP SOPRA STERIA GROUP SA
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
BIO BB BIOTECH AG
POM PLASTIC OMNIUM SE
MERY MERCIALYS SA
ASY ASSYSTEM SA
BEN BENETEAU SA
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
FII LISI SA
LSS LECTRA SA
LNA LNA SANTE SA
GBT GUERBET SA
ATE ALTEN SA
ACX ACERINOX SA
FR VALEO SE
BAMNB KONINKLIJKE BAM GROEP NV
FAE FAES FARMA S.A.
COFB COFINIMMO SA
SUN SULZER AG
TUB TUBACEX S.A.
HEIJM HEIJMANS N.V. CERT
MBWS
CTAC MARIE BRIZARD WINE & SPIRITS SA
PAL CTAC N.V.
CON PALFINGER AG
LIGHT CONZZETA AG
NVG SIGNIFY NV
WBD NAVIGATOR COMPANY SA
RENE WEBUILD S.P.A.
ROVI REDES ENERGETICAS NACIONAIS SA
COL LABORATORIOS FARMACEUTICOS ROVI S.A.
ALM INMOBILIARIA COLONIAL SOCIMI SA
TEC ALMIRALL SA
HOME TECHNIPFMC PLC
VOS NEINOR HOMES SA
2CRSI VOSSLOH AG
VK 2CRSI SA
WDP VALLOUREC SA
ALHG WAREHOUSES DE PAUW SCA
LOUIS HACHETTE GROUP
- Nicolas Thorez
- Nicolas Thorez
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Add...
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic i...
Abivax Announces Pricing of $650M (€554M) Public Offering of American ...
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...
Abivax announces trading resumption of its ordinary shares on Euronext...
Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...
- Jeremy Garnier
Abivax announces temporary trading halt of its ordinary shares on Euro...
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its Amer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.